The neuropathic pain market is forecast to double from 2006 to reach over $7 billion by 2016. At this time, the current late-stage neuropathic pain pipeline is forecast to take only 18% of the total market share, highlighting an opportunity for better

The continued uptake of existing brands and the launch of two opioid antagonists will cause the market to grow at a compound annual growth rate of 13.5% from 2006 to reach $304m across the seven major markets by 2016. The alcohol dependence market requ

Iincretin mimetics is to emerge as a major new therapeutic class in non-insulin antidiabetics, driven by an explosion in the patient population, safety fears surrounding established therapies and significant unmet patient needs.

Supportive care can be defined as those products used to prevent and/or treat the adverse side effects that arise as a result of the tumor itself or administration of anticancer therapies, in particular cytotoxic chemotherapy. While the antihormonal th

In 2007, more than 3 million new cases of solid tumors are forecast to be diagnosed across the seven major pharmaceutical markets, obviously representing an enormous market potential. Lower incidence tumor types are becoming increasingly attractive to

Detailed analysis of Disease Modifying Anti-Rheumatic Drugs (DMARDs) in the pipeline, including an assessment of the latest trial data and clinical strategies. Includes an indication specific ten-year forecast for future key products.

Analysis of disease-modifying drugs in late-stage clinical development for use in osteoporosis, including important clinical trial results, patient potential, market potential, and forecasts to 2016; supported by key opinion leader comments.

Analysis of the future Huntington’s disease market with revenue forecasts of key late-stage pipeline drugs and epidemiological scenario based forecasts to 2016. Conclusions are supported by key opinion leader and industry executive comments.

Overview of the products under clinical development for hematological malignancies. This includes an in-depth review and analysis of the late-phase candidates, sales forecasts to 2016, drug assessments and key opinion leader insights.

In-depth review of developmental drugs for the acute stroke market. Explores the commercial prospects of new agents against existing products and profiles unmet market needs as well as unmet clinical needs, and provides sales forecasts to 2017.

Gastroesophageal reflux disease (GERD), functional dyspepsia (FD) and peptic ulcer disease (PUD) represent a group of common gastrointestinal (GI) conditions, which can be referred to collectively as upper GI disorders. Gastric acid suppression remains

Analysis of drugs in late-stage clinical development for use in insomnia, including important clinical trial results, patient potential, market potential, and forecasts to 2016; supported by key opinion leader comments.

Treatment of HIV has come a long way since the discovery of the virus. Although no real cure has been found yet, the last few decades have seen the introduction of many classes of drugs that suppress the replication of the virus. As therapeutics have i

As the reimbursement status for the cost of hospital-acquired infections is under pressure by payors, interest in preventing these complications at the outset is growing. Nosocomial vaccines offer one route of prevention. This report assesses the clini

Analysis of disease-modifying drugs in late-stage clinical development for use in multiple sclerosis, including important clinical trial results, patient potential, market potential, and forecasts to 2016; supported by key opinion leader comments.

Overview of the late-phase pipeline for NSCLC, SCLC, mesothelioma, brain, head and neck, and thyroid cancer; analysis of key products, clinical trial data, sales forecasts to 2017, Datamonitor drug assessment summaries and opinion leader insights.

Analysis of the acute and chronic heart failure pipeline across seven major markets.

In-depth review of developmental drugs for the dyslipidemia market. Explores the commercial prospects of new agents against existing products, profiles unmet needs, and provides sales forecasts for the developmental agents to 2016.

The ALS market was worth $148m in 2006 across the seven major markets. With the only approved treatment for ALS, Sanofi-Aventis’s Rilutek (riluzole), facing generic incursion in 201213, future growth in this market is dependent on the success of

Incidence of breast cancer in the seven major markets will total 455,000 in 2008, while 115,000 women will die from the disease. Despite advances in treatment over the past decade, significant unmet needs remain. This level of demand and the large pati

Datamonitor believes that companies developing pipeline drugs for the depression market should concentrate resources on targeting third-line depression patients, a market with significant sales volume and few viable treatment options. GSK’s gepir

Overview of the pipeline molecular targeted cancer therapies (MTTs). This includes an in-depth review and analysis of the late-phase candidates, their sales forecasts to 2016, drug assessments, key opinion leader insights and pipeline dynamics.

Given an enhanced understanding of the biological basis for oncogenesis and the benefit of immunotherapy approaches such as Genentech/Roche`s Rituxan, it is no surprise that targeted treatments and immunotherapy dominate the pipeline. Integrating these

Datamonitor estimates the total revenue generated from new antithrombotics in the seven major markets will reach approximately $10bn by 2015, with novel oral anticoagulants contributing over 70% to this volume. However, barriers to entry exist and deve

There is a clear need for new treatments for heart failure, as mortality and morbidity rates, although improving, remain high. Heart failure already represents the leading cause of hospitalization for patients over the age of 65 in Western markets and